Premium
Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia
Author(s) -
Faraci Maura,
Micalizzi Concetta,
Lanino Edoardo,
Scuderi Francesca,
Morreale Giuseppe,
Dini Giorgio,
Cappelli Barbara,
Dallorso Sandro
Publication year - 2005
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2005.00372.x
Subject(s) - medicine , juvenile myelomonocytic leukemia , discontinuation , hematopoietic stem cell transplantation , transplantation , surgery , stem cell , pediatrics , haematopoiesis , genetics , biology
Abstract: Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is the only cure for juvenile myelomonocytic leukaemia (JMML), but relapse remains the major cause of failure. A second transplant may be considered a way to induce the graft vs. leukaemia effect in patients who relapse after their first HSCT. We describe a 7‐month‐old girl with JMML who relapsed after a first, related allo‐HSCT, and who again relapsed 8 months after the second transplant, despite discontinuation of immusuppressive therapy. She underwent a third allogeneic transplant from another related donor. At the time of this report the patient is in complete remission 26 months after the third transplant. We suggest that a third allo‐HSCT may be taken into consideration for JMML patients who experience relapse, even after two previous transplants.